The estimated Net Worth of Mark Kaufmann is at least $1 Milhão dollars as of 7 October 2019. Mark Kaufmann owns over 20,000 units of Ardelyx Inc stock worth over $962,051 and over the last 10 years Mark sold ARDX stock worth over $38,276.
Mark has made over 8 trades of the Ardelyx Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Mark exercised 20,000 units of ARDX stock worth $10,800 on 7 October 2019.
The largest trade Mark's ever made was exercising 20,000 units of Ardelyx Inc stock on 7 October 2019 worth over $10,800. On average, Mark trades about 4,286 units every 112 days since 2015. As of 7 October 2019 Mark still owns at least 161,418 units of Ardelyx Inc stock.
You can see the complete history of Mark Kaufmann stock trades at the bottom of the page.
Mark's mailing address filed with the SEC is 34175 Ardenwood Blvd, Fremont, CA 94555, USA.
Over the last 10 years, insiders at Ardelyx Inc have traded over $37,312,621 worth of Ardelyx Inc stock and bought 85,247,838 units worth $820,614,871 . The most active insiders traders include Forest Baskett, Scott D Sandell, eAnthony A. Jr. Florence. On average, Ardelyx Inc executives and independent directors trade stock every 12 days with the average trade being worth of $1,784,764. The most recent stock trade was executed by Michael Raab on 27 August 2024, trading 7,500 units of ARDX stock currently worth $46,650.
ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.
Ardelyx Inc executives and other stock owners filed with the SEC include: